1. Forskningssamverkan –olika modeller
Stockholm, May
Amy Leval, Outcomes Research Manager, Med Dr Epidemiologi, Janssen

2. Interactive Visualization - Visualizing Prostate Cancer Testing and Outcomes -

3. Video link

7. Who are we? Olof Akre Markus Aly Sandra Eloranta Amy Leval
Urologist
Professor KI
Markus Aly
Urologist, Ph.D.
Karolinska University Hospital
Sandra Eloranta
Researcher
Med. Sci. KI
Amy Leval
Researcher
Janssen
Johan Liwing
RWE Partnerships
Janssen
Mario Romero
Visualization
Professor KTH
To be continued…

8. From collaborative visualization to collaborative analytics

9. OHDSI community
•>140 researcher institutions in academia, industry, government, health systems
• Common data model (OMOP)
•>20 countries
•>660 million patients

10. Collaborative analytics – current possibility, future standard?
11 data sources, 4 countries, 250 million patients
Common data modell.
Dela på protokoll, analysresultat, inte på individdata!

11. Yet another way to collaborate….

14. Janssen’s global real world evidence network
By analyzing a broader range of parameters, real world evidence research can uncover outcomes, unmet needs and clues to future medical breakthroughs.
Janssen is partnering with top institutions world wide to accelerate this new line of research.
Our network aims to:
Apply scientific best practices
Advance methodologies
Generate evidence about disease pathways, healthcare delivery, and the effects of medical interventions
Support medical decisions and identify new medical breakthroughs
Sweden
Canada
Hungary
USA
Korea
Taiwan
By forming a global real world evidence network, Janssen is taking an industry leading initiative to accelerate real world evidence research.
Real World Evidence research is based on studying healthcare data to identify outcomes, cost of care, unmet needs, and potential ways to improve treatment.
Adding other parameters such as socio-economic data and data from Randomized Clinical Trials, research can reveal even more information that is useful in healthcare decision making and development of new therapeutic solutions.
This is an emerging field of research with great potential. At this point, it is important to improve methodology, sourcing of data and to produce scientific results that can be put into practice.
Janssen’s global research network enables a joint and collaborative approach to further advanced real world evidence research.
Collaborations in Sweden with Karolinska Institutet. In Canada with University of Alberta. In the US with Optum and UPENN. In Hungary, Korea and Taiwan with national data sources.

15. Unique opportunity for Nordic life science
Real world evidence will impact all phases of medical research and therapeutic development.
Thanks to its data infrastructure, the Nordic region can become a hot-spot for advanced medical research by enabling uniquely comprehensive and long term studies.
Janssen is partnering with Karolinska Institutet in a major collaborative research initiative that focuses on:
Treatment resistant depression
Prostate cancer
Psoriasis
B-Cell malignancies
Methodology development
Janssen’s real world evidence network also facilitates collaboration in other disease areas, across Nordic institutions.
As we learn more and more about how to use real world evidence, it will gradually play a bigger role in how we conduct medical research and develop new therapeutic solutions.
Opportunity for Nordic life science
The Nordic region has unique registries (thanks to identification numbers; it’s possible to link several parameters, over long time periods)
The Nordic region has a research tradition in Real World Evidence, currently producing a major portion of all global research
The research produced today mostly focus on registry research – there’s a potential to develop Nordic research into advanced Real World Evidence research that integrate a larger number of data sources.
Nordic research could in the future offer unique opportunities to study a complex series of data over long periods of time.
Our collaboration with Karolinska Institutet is based on advanced Real World Evidence research
Initial 3-year program with joint research team
Will initially focus on (see slide)
Some of the unique features are: integrate Janssen’s clinical data (YODA) and observational data from multiple Janssen sources to investigate and benchmark against Swedish sources – this collaborative combined data and research collaboration will enable unique insights that either party could not achieve on its own.
We are looking for new and extended partnerships in the Nordic region
We have a long history of data research in the Nordics years collaborating with Karolinska Institutet. Approx. 100 research partnerships in the Nordics covering almost all therapeutic areas.
Our global Real World Evidence Network enable us to initiate new partnerships and we are happy to embrace Nordic institutions in our global Real World Evidence Network.
10%
Of all global real world evidence research originates from Sweden. Other Nordic countries are also generating an extensive proportion.

16. Broad collaboration: Johnson & Johnson Innovation + Karolinska Institutet Launched 22 May 2015
A broad and unique industry-academia collaboration in the Nordic region to:
advance medical research
nurture emerging healthcare companies
accelerate development of breakthrough products for improved treatment outcomes
To support the collaboration Johnson & Johnson Innovation opened a life science innovation office at Karolinska Institutet.
Commercial knowledge
Resources
Coaching
Investment
Seed-financing
Innovation focus (KI Innovations AB)
Abundance of early-stage science
World class life sciences research
Nordic influence
Academic excellence
Prestige
History

17. “IMI is the world's biggest public-private partnership (PPP) in the life sciences. Through the IMI 2 programme, it has a €3.3 billion budget for the period  ”

18. IMI’s Big Data for Better Outcomes (BD4BO)

19. Samverkan – topp 3 checklista
1.Förståelse kring den vetenskapliga frågeställningen 2.Uppskatta kompetens hos olika team - ta in mer extern kompetens vid behov… 3.Kontrakt, och tid för kontrakt och process

20. Samverkan för att utveckla life science
Det finns flera modeller